Most health assessments focus on either the past (genetics, family history) or the future (lifetime risk). Real-time risk assessment is different: it measures biological signals circulating in your body right now, providing a snapshot of your current cancer risk.
Looks at inherited DNA changes that may increase lifetime risk, but does not change over time.
Provide estimated probabilities based on behaviours and exposures.
Detect structural or advanced disease, often after changes are already visible.
Detects molecular signals in blood that can appear long before symptoms, imaging findings, or conventional screening.
Cancer develops gradually, but biological signals can emerge much earlier than symptoms. Real-time risk assessment:
Rather than relying on static historical information
Giving physicians additional context for follow-up
Results can change over time, making repeated assessments valuable for long-term prevention strategies. Some clinicians have noted case reports where new cancer signals appeared within six to eight months after a negative colonoscopy.
The miRoncol Real-time Multi-Cancer Early Risk Assessment provides a snapshot of your current molecular signals. Because these patterns can change over time, many individuals choose to repeat the test annually as part of their health checkup or more often if guided by their physician. The right frequency depends on your personal risk factors, age, and preventive care plan.
MicroRNAs are small molecules that regulate gene expression and circulate in blood. When analyzed with advanced AI models, their patterns can reveal meaningful information about early-stage cancer biology across multiple tumour types.
Real-time cancer risk assessment gives you and your physician an earlier opportunity to take action transforming prevention into a continuous part of your health journey